Campath Antitrust Order Focuses On Off-Label Use In Organ Transplant Market
This article was originally published in The Pink Sheet Daily
Schering AG will take over sole rights for development and marketing of Campath as acute therapy for solid organ transplant rejection as a result of the Genzyme/Ilex merger
You may also be interested in...
Genzyme closes $1 bil. deal the day after receiving Federal Trade Commission approval. Clolar could be Genzyme's first direct presence in oncology therapeutic market; FDA's user fee deadline is Dec. 30.
Meeting to address opioid abuse crisis was also a trial of whether FDA could conduct important public business using online-only technology.